Reactivation of Hepatitis B Infection During the Cause of Non Hodgkin's Lymphoma Chemotherapy

Authors

  • Diana Jeni H Department of Internal Medicine, Faculty of Medicine, University of Brawijaya/Dr. Saiful Anwar General Hospital, Malang
  • Syifa Mustika Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, University of Brawijaya/Dr. Saiful Anwar General Hospital, Malang

DOI:

https://doi.org/10.24871/1522014115-119

Abstract

Hepatitis due to hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy is a serious cause of liver-related morbidity and mortality. Frequently used combination regimens in Non-Hodgkin’s lymphoma are cyclophosphamide, hydroxydaunomycin (adriamycin), vincristine (oncovin), and prednison (CHOP). The use of rituximab, a monoclonal antibody targeting CD20 antigen present in benign and malignant B-cells, in combination with systemic chemotherapy has resulted in an improved duration of remission and survival for this patients. Rituximab is a HBV reactivation risk factor even greater than corticosteroids in a series of patients with lymphoma treated with combined-modality treatment (CMT).

A 43 years old female patient who already diagnosed with Non-Hodgkin’s lymphoma, came with chief complain nausea and vomiting for three weeks. The patient recently got hospitalized with icteric and known have positive HBsAg. She received chemotherapy rituximab CHOP (R-CHOP) for four times and got rituximab in the last chemotherapy. Previously she had icteric and increased liver function test. After exclude other possibility causes this symptom and sign, it was concluded this is HBV reactivation. The chemotherapy was postponed until this reactivation of hepatitis B resolved and start giving lamivudine two weeks before reintroduce chemotherapy.

Keywords: antiviral treatment, chemotherapy, hepatitis B virus, reactivation

Downloads

Published

2014-08-01

How to Cite

H, D. J., & Mustika, S. (2014). Reactivation of Hepatitis B Infection During the Cause of Non Hodgkin’s Lymphoma Chemotherapy. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 15(2), 115–119. https://doi.org/10.24871/1522014115-119

Issue

Vol. 15 No. 2 (2014): VOLUME 15, NUMBER 2, August 2014

Section

Case Reports

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).